Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$573.9 million.

  • Cytokinetics' Net Income towards Common Stockholders fell 18.95% to -$178.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$602.1 million, marking a year-over-year decrease of 7.41%. This contributed to the annual value of -$573.9 million for FY2024, which is 9.43% down from last year.
  • Latest data reveals that Cytokinetics reported Net Income towards Common Stockholders of -$573.9 million as of FY2024, which was down 9.43% from -$524.5 million recorded in FY2023.
  • Cytokinetics' Net Income towards Common Stockholders' 5-year high stood at -$109.9 million during FY2020, with a 5-year trough of -$573.9 million in FY2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$480.7 million, with a median of -$524.5 million in 2023.
  • Data for Cytokinetics' Net Income towards Common Stockholders shows a maximum YoY tumbled of 84.48% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Cytokinetics' Net Income towards Common Stockholders stood at -$109.9 million in 2020, then tumbled by 84.48% to -$202.8 million in 2021, then crashed by 69.48% to -$343.6 million in 2022, then crashed by 52.64% to -$524.5 million in 2023, then dropped by 9.43% to -$573.9 million in 2024.